https://orcid.org/0009-0001-2181-3145
References
- Wind J, Mahajan V. Designing product and business portfolio. Harvard Bus Rev. 1981;59:155–165.
- Lafontaine F, Slade M. Franchising and exclusive distribution. In: The Oxford Handbook of International Antitrust Economics. Vol. 2. Oxford; 2014:387.
- Bleys J, Coravos J, Fleming E, Quigley D. A new portfolio model for biotech. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/a-new-portfolio-model-for-biotech. Accessed November 11, 2022.
- Sun L, Li S, Peng X. Should additional value elements be included in cost-effectiveness analysis in pharmacoeconomic evaluation: a novel commentary. Cost Eff Resour Alloc. 2023;21(1):79. doi:10.1186/s12962-023-00490-4
- Daller J. Biosimilars: a consideration of the regulations in the United States and European Union. Regul Toxicol Pharmacol. 2016;76:199–208. doi:10.1016/j.yrtph.2015.12.013
- U.S. Food & Drug Administration. Biosimilar product information. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed January 17, 2024.
- European Medicines Agency. Search results. European Medicines Agency. Available from: https://www.ema.europa.eu/en/search?f%5B0%5D=ema_med_status%3A100108&f%5B1%5D=ema_medicine_bundle%3Aema_medicine&f%5B2%5D=ema_search_categories%3A83&f%5B3%5D=ema_search_topics%3A45&landing_from=73303. Accessed January 17, 2024.
- IQVIA. Biosimilars in the United States 2020–2024. IQVIA; 2020. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/biosimilars-in-the-united-states-2020-2024#:~:text=1%20Currently%2C%2013%25%20of%20biosimilar%20products%20in%20development,developed%20and%20launched%20by%20seven%20large%20pharma%20companies. Accessed January 17, 2024.
- Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. US payer perspectives on evidence for formulary decision making. J Oncol Pract. 2012;8(3 Suppl):22s–7s. doi:10.1200/jop.2011.000526
- Sendyona S, Odeyemi I, Maman K. Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. J Mark Access Health Policy. 2016;4. doi:10.3402/jmahp.v4.31660
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
- Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–372. doi:10.1007/s40259-014-0088-z
- Shukar S, Zahoor F, Hayat K, et al. Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol. 2021;12:693426. doi:10.3389/fphar.2021.693426
- Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
- Griffith N, McBride A, Stevenson JG, Green L. Formulary selection criteria for biosimilars: considerations for US health-system pharmacists. Hosp Pharm. 2014;49(9):813–825. doi:10.1310/hpj4909-813
- Jacoby R, Smith E, Wilkins D, Divya I, Peltre S. Winning with biosimilars Opportunities in global markets Available from: https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-biosimilars-whitepaper.pdf. Accessed November 11, 2022.
- Pfizer. Biosimilar implementation: potential best practices and other considerations Available from: https://www.pfizerbiosimilars.com/images/sites/default/files/Downloadables/PP-BIO-USA-0624%20Leave-Behind_DIGITAL.pdf. Accessed November 11, 2022.
- Pacific Business Group on Health. Biosimilar uptake: the physician perspective. Available from: https://www.pbgh.org/wp-content/uploads/2021/01/Biosimilars-from-the-physician-perspective-FINAL.pdf. Accessed November 11, 2022.
- U.S. Pharmacist. Biosimilar IV and SC trastuzumab in clinical practice; 2022. Available from: https://www.uspharmacist.com/article/biosimilar-iv-and-sc-trastuzumab-in-clinical-practice. Accessed February 23, 2024.
- Waller CF, Möbius J, Fuentes-Alburo A. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. Br J Cancer. 2021;124(8):1346–1352. doi:10.1038/s41416-020-01255-z
- Whitemore M. Future biosimilars: pros and cons. Available from: https://www.hemophiliafed.org/future-bisomilars-pros-and-cons/. Accessed November 11, 2022.
- Garg M, Chatterjee A, Chambers CR. Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada. J Oncol Pharm Pract. 2021;27(5):1189–1194. doi:10.1177/10781552211007535
- Oskouei ST, Kusmierczyk AR. Biosimilar uptake: the importance of healthcare provider education. Pharmaceut Med. 2021;35(4):215–224. doi:10.1007/s40290-021-00396-7
- Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13:917814. doi:10.3389/fphar.2022.917814
- Cha M, Yu F. Pharma’s first-to-market advantage. McKinsey and Company. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/pharmas-first-to-market-advantage. Accessed August 15, 2023.
- Hopkins JS, Uribe A. Pfizer-BioNTech Covid-19 vaccine is world’s preferred shot. The Wall Street Journal. Available from: https://www.wsj.com/articles/pfizer-biontech-covid-19-vaccine-is-worlds-preferred-shot-11633950181. Accessed May 15, 2023.
- Berger J, Draganska M, Simonson I. The influence of product variety on brand perception and choice. Marketing Sci. 2007;26(4):460–472. doi:10.1287/mksc.1060.0253
- Costantino N, Pellegrino R. Choosing between single and multiple sourcing based on supplier default risk: a real options approach. J Purchasing Supply Manage. 2010;16(1):27–40. doi:10.1016/j.pursup.2009.08.001
- Goodman C, Villarivera C, Gregor K, van Bavel J. Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the U.S. market: opportunities for reform. J Manag Care Spec Pharm. 2019;25(11):1174–1181. doi:10.18553/jmcp.2019.19167